NY-CELONIS
Celonis , the global leader in execution management, announced the acquisition of Process Analytics Factory GmbH (PAF), a leading provider of process mining insights for Microsoft Power BI. This acquisition will enable millions of Microsoft Power Platform users to utilize Celonis’ market leading Execution Management System (EMS) for process mining, automation, and collaboration.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220329005245/en/
The acquisition of PAF is part of Celonis’ strategy to enable companies everywhere and in all industries to use process mining within the Celonis EMS to reveal and fix process inefficiencies. Celonis is committed to empowering users of the top automation, collaboration, and workflow platforms to run their businesses using Celonis’ unique process insights and intelligent, targeted actions.
The PAFnow process mining product is completely integrated into Microsoft Power BI and Microsoft Office 365 for the analysis, visualization and optimization of almost any process. 97 percent of the Fortune 500, and over 260,000 companies globally, use Microsoft Power BI.
The Celonis EMS combines, in one integrated cloud platform, real-time data, process intelligence, and targeted action to impact top, bottom, and greenline business performance at speed. Customers looking to get full clarity on how their business processes are running - whether across supply chains, shared service centers, or system landscapes - can now benefit from the unique and advanced capabilities of the Celonis EMS within their familiar Microsoft environments.
Maximilian Gerbert, project lead at Mercedes-Benz Management Consulting, said: “We - the Digital Accelerator of Mercedes-Benz - are a data-driven department with a business intelligence strategy built over years, but once we brought process mining into our BI infrastructure we were able to see the full picture and identify process inefficiencies throughout our company that we never could before. When supply chain issues come up, we use insights from process mining within BI to pinpoint the bottlenecks and take action to fix them — before they impact our cash flow and our customer experience. We are excited by the news of the Celonis acquisition and the ability to leverage the powerful capabilities of the Celonis EMS within our Microsoft environment.”
"It’s great to see Celonis and PAF join forces,” said Linus Linder, Head of IT at Muller - Die lila Logistik Service GmbH. “Now we can benefit from the real-time data, process intelligence, and targeted action in the Celonis EMS within our familiar Microsoft Power BI environment."
The rapid adoption of the Celonis EMS comes on the heels of a generational shift to use process insights and intelligence to change how businesses are run.
According to Gartner® the market for hyper-automation software will reach nearly $860 billion by 20251 . But many businesses do not maximize the value of their digital investments because they lack insight into outdated processes holding back business operations. According to a Forrester report commissioned by Celonis, process mining has hit an inflection point in 2022 as decision makers demand better execution by finding and fixing process inefficiencies.
“Since we started 11 years ago, the Celonis mission has always been the same - to help our customers reach the full potential of their business performance by removing process inefficiencies - and that requires Celonis to be everywhere,” said Alex Rinke, co-CEO and co-founder of Celonis. “The PAF acquisition enables the millions of users of the Microsoft Power Platform to use Celonis’ unique data and intelligent insights to power analytics, automation, and collaboration.”
“This combination leverages the strength of Celonis market leadership with the foundation that PAF has created in the Microsoft Power Platform. This allows our companies to build the bridge between the Microsoft Power Platform and the Celonis Execution Management System,” said Tobias Rother, CEO and founder of PAF. “We are thrilled to help put Celonis into the hands of such a large and fast-growing community of business leaders.”
“In our inaugural HFS SaaS XXV 2022 report we ranked Celonis as the top private SaaS company in Overall Rank, Business Value Creation, Partner Engagement, and OneOffice Alignment,” said Phil Fersht, CEO and Chief Analyst of HFS Research. “The acquisition of PAF demonstrates why Celonis is ranked alongside Microsoft, Salesforce, Amazon, Adobe, and Google for shaping the future of native automation, data, and process design. Celonis is strategically moving its unique process data and intelligent insights into the world’s largest work, automation, and analytics platforms.”
"The purpose of process mining is to gain a fact-based understanding of business process variance and inefficiency to systematically improve processes to maximize performance while aligning with the overall goals of a business. Embedding process mining into common analytics platforms makes it easier for teams to work together using familiar tools,” said Maureen Fleming, Program Vice President for the IDC Intelligent Process Automation Market Research and Advisory Service.
The PAFnow software capabilities will debut in Celonis Experiences at Celonis World Tour 2022 . Celonis Experiences will showcase how customers can seamlessly integrate Celonis EMS with Microsoft Power BI reporting, collaborate with Microsoft Teams, and trigger flows in Microsoft Power Automate.
About Celonis
Celonis helps organizations to execute on their data. Powered by its market-leading process mining core, the Celonis Execution Management System provides a set of applications, a developer studio and platform capabilities for business executives and users to eliminate billions in corporate inefficiencies, provide better customer experience and reduce carbon emissions. Celonis has thousands of implementations in global customers and is headquartered in Munich, Germany and New York City, USA with 20 offices worldwide.
© 2022 Celonis SE. All rights reserved. Celonis, Execution Management System, EMS and the Celonis “droplet” logo are trademarks or registered trademarks of Celonis SE in Germany and other jurisdictions. All other product and company names are trademarks or registered trademarks of their respective owners.
1 Gartner, Forecast Analysis: Hyperautomation of Enablement Software, Worldwide, Cathy Tornbohm, Fabrizio Biscotti, Rachel Chippendale, March 22, 2021.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220329005245/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom